Albumin (human) is under clinical development by Grifols and currently in Phase III for Decompensated Cirrhosis. According to GlobalData, Phase III drugs for Decompensated Cirrhosis does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Albumin (human) LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Albumin (human) overview
Human Albumin (Albiomin, Albumin, Albutein, Plasbumin, Albuplan) is obtained by fractionation of blood plasma. It is formulated as solution for intravenous route of administration. Albutein is indicated for the treatment of hypoalbuminemia, restoration and maintenance of circulating blood volume where it is shown a deficit of volume and use of a colloid is appropriate. Plasbumin is indicated for the treatment of adult respiratory distress syndrome, burns, hypovolemic shock, liver failure. Albutein was under development for kidney transplant.
It is under development for the treatment of decompensated cirrhosis and uncomplicated ascites. It was also under development for amyotrophic lateral sclerosis, Alzheimer's disease, hepatic encephalopathy and septic shock.
Grifols overview
Grifols develops, produces, and markets plasma-derived medicines and transfusion medicines. The company is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. The company’s major products include essential plasma-derived medicines for treating conditions across various therapeutic areas such as neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.
For a complete picture of Albumin (human)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
